Ian S Cohn, Bethan A Wallbank, Breanne E Haskins, Keenan M O'Dea, Ryan D Pardy, Sebastian Shaw, Maria I Merolle, Jodi A Gullicksrud, David A Christian, Boris Striepen, Christopher A Hunter
{"title":"Intestinal cDC1s provide cues required for CD4+ T cell-mediated resistance to Cryptosporidium.","authors":"Ian S Cohn, Bethan A Wallbank, Breanne E Haskins, Keenan M O'Dea, Ryan D Pardy, Sebastian Shaw, Maria I Merolle, Jodi A Gullicksrud, David A Christian, Boris Striepen, Christopher A Hunter","doi":"10.1084/jem.20232067","DOIUrl":null,"url":null,"abstract":"<p><p>Cryptosporidium is an enteric pathogen and a prominent cause of diarrheal disease worldwide. Control of Cryptosporidium requires CD4+ T cells, but how protective CD4+ T cell responses are generated is poorly understood. Here, Cryptosporidium parasites that express MHCII-restricted model antigens were generated to understand the basis for CD4+ T cell priming and effector function. These studies revealed that parasite-specific CD4+ T cells are primed in the draining mesenteric lymph node but differentiate into Th1 cells in the gut to provide local parasite control. Although type 1 conventional dendritic cells (cDC1s) were dispensable for CD4+ T cell priming, they were required for CD4+ T cell gut homing and were a source of IL-12 at the site of infection that promoted local production of IFN-γ. Thus, cDC1s have distinct roles in shaping CD4+ T cell responses to an enteric infection: first, to promote gut homing from the mesLN, and second, to drive effector responses in the intestine.</p>","PeriodicalId":15760,"journal":{"name":"Journal of Experimental Medicine","volume":"221 7","pages":""},"PeriodicalIF":12.6000,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11148471/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Experimental Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1084/jem.20232067","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/6/3 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Cryptosporidium is an enteric pathogen and a prominent cause of diarrheal disease worldwide. Control of Cryptosporidium requires CD4+ T cells, but how protective CD4+ T cell responses are generated is poorly understood. Here, Cryptosporidium parasites that express MHCII-restricted model antigens were generated to understand the basis for CD4+ T cell priming and effector function. These studies revealed that parasite-specific CD4+ T cells are primed in the draining mesenteric lymph node but differentiate into Th1 cells in the gut to provide local parasite control. Although type 1 conventional dendritic cells (cDC1s) were dispensable for CD4+ T cell priming, they were required for CD4+ T cell gut homing and were a source of IL-12 at the site of infection that promoted local production of IFN-γ. Thus, cDC1s have distinct roles in shaping CD4+ T cell responses to an enteric infection: first, to promote gut homing from the mesLN, and second, to drive effector responses in the intestine.
隐孢子虫是一种肠道病原体,也是全球腹泻病的主要病因。控制隐孢子虫需要 CD4+ T 细胞,但人们对如何产生保护性 CD4+ T 细胞反应知之甚少。在此,我们生成了表达 MHCII 限制性模型抗原的隐孢子虫寄生虫,以了解 CD4+ T 细胞启动和效应器功能的基础。这些研究发现,寄生虫特异性 CD4+ T 细胞在引流的肠系膜淋巴结中启动,但在肠道中分化成 Th1 细胞,以提供局部寄生虫控制。虽然 1 型传统树突状细胞(cDC1s)对 CD4+ T 细胞的引诱是不可或缺的,但它们却是 CD4+ T 细胞肠道归巢所必需的,并且是感染部位 IL-12 的来源,可促进 IFN-γ 的局部产生。因此,cDC1s 在形成 CD4+ T 细胞对肠道感染的反应方面具有不同的作用:首先,促进从 mesLN 的肠道归巢;其次,驱动肠道中的效应器反应。
期刊介绍:
Since its establishment in 1896, the Journal of Experimental Medicine (JEM) has steadfastly pursued the publication of enduring and exceptional studies in medical biology. In an era where numerous publishing groups are introducing specialized journals, we recognize the importance of offering a distinguished platform for studies that seamlessly integrate various disciplines within the pathogenesis field.
Our unique editorial system, driven by a commitment to exceptional author service, involves two collaborative groups of editors: professional editors with robust scientific backgrounds and full-time practicing scientists. Each paper undergoes evaluation by at least one editor from both groups before external review. Weekly editorial meetings facilitate comprehensive discussions on papers, incorporating external referee comments, and ensure swift decisions without unnecessary demands for extensive revisions.
Encompassing human studies and diverse in vivo experimental models of human disease, our focus within medical biology spans genetics, inflammation, immunity, infectious disease, cancer, vascular biology, metabolic disorders, neuroscience, and stem cell biology. We eagerly welcome reports ranging from atomic-level analyses to clinical interventions that unveil new mechanistic insights.